| ASH 2018: Three Up, Two Down as Big Blood Disease Meeting Rolls On | Ben Fidler | 12/03/18 | National |
| ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More | Alex Lash | 11/26/18 | National |
| Allogene’s IPO Raises $288M for Tests of “Off-the-Shelf” Cell Therapy | Frank Vinluan | 10/11/18 | San Francisco |
| Six Life Science Firms Close Q3 with an IPO, More Are on the Way | Frank Vinluan | 09/28/18 | Boston |
| Bio Roundup: CRISPR Ruling, “America’s Nobels,” IPOs & More | Frank Vinluan | 09/14/18 | National |
| Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs | Frank Vinluan | 08/30/18 | San Francisco |
| ASCO Wrap: Cancer Combos, Precision Meds, Stock Movers & More | Ben Fidler | 06/05/18 | National |
| Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results | Ben Fidler | 05/29/18 | San Francisco |
| With New Data, Karyopharm Says It Will Ask for Myeloma Approval | Ben Fidler | 04/30/18 | Boston |
| Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More | Frank Vinluan | 03/30/18 | National |
| With $20B to Spend, Sanofi, Celgene Bet Big on Hemophilia, CAR-T | Ben Fidler | 01/22/18 | National |
| Cellectar Biosciences Shutting Down Manufacturing Operations | Jeff Buchanan | 01/08/18 | Wisconsin |
| Bio Roundup: Tax Cuts, a Funding Rush, Hemophilia Questions & More | Alex Lash | 12/15/17 | National |
| ASH 2017 Highlights: CAR-T Competition, Myeloma, Hemophilia & More | Alex Lash | 12/11/17 | National |
| Promega, Cellectar, Blockchain, & More: This Week’s WI Watchlist | Jeff Buchanan | 12/08/17 | Wisconsin |
| Gilead Bets on Cell Therapy Again with $567M Cell Design Labs Deal | Frank Vinluan | 12/07/17 | San Francisco |
| Bio Roundup: RNAi Drama, Immunotherapy Data, Lasker Winners & More | Ben Fidler | 09/08/17 | National |
| Immunotherapy Safety Worries Halt Celgene Myeloma Study, Slow 5 Others | Alex Lash | 09/07/17 | New York |
| To Be More Than Quick Splash, Gilead’s CAR-T Purchase Faces Hurdles | Alex Lash | 08/28/17 | San Francisco |
| Celgene Narrows Its Relationship With Sutro, No Acquisition Coming | Alex Lash | 08/10/17 | New York |
| Bio Roundup: GOP Drama, Immunotherapy Setbacks, Pharma Revamps | Ben Fidler | 07/28/17 | National |
| In a Myeloma Setback, Merck Halts Studies Due to Patient Deaths | Ben Fidler | 06/12/17 | New York |
| Dragonfly, Tyler Jacks’s Disney-Backed Startup, Gets $33M in Celgene Deal | Ben Fidler | 06/12/17 | Boston |
| Keeping Focus on Cancer, Karyopharm Licenses Antiviral to Anivive | Frank Vinluan | 05/04/17 | Boston |
| AACR Review: Biden Fired Up, Incyte Doubles Up, BMS Up And Down | Alex Lash | 04/06/17 | National |
| Possible Cures. Mystery Deaths. Daunting Costs. Can CAR-T Be Tamed? | Alex Lash | 03/13/17 | National |
| WARF, Cellectar Expand Licensing Agreement For Blood Cancer Drug | Jeff Buchanan | 03/10/17 | Wisconsin |
| After Navigating Ups and Downs, Cellectar CEO Caruso Looks to Future | Jeff Buchanan | 02/21/17 | Wisconsin |
| Lynx Bio Makes Headway on New Diagnostic for Blood Cancer Drugs | Jeff Buchanan | 02/13/17 | Wisconsin |
| Cellectar Awarded Another Cancer Drug Patent | Jeff Buchanan | 01/26/17 | Wisconsin |
